公开(公告)号：US11634409B2

公开(公告)日：2023-04-25

申请号：US17745346

申请日：2022-05-16

申请人： Array BioPharma Inc.

发明人： Patrick Michael Barbour ,  Katie Keaton Brown ,  Adam Wade Cook ,  Erik James Hicken ,  Dean Russell Kahn ,  Ellen Ruth Laird ,  Andrew Terrance Metcalf ,  David Austin Moreno ,  Bradley Jon Newhouse ,  Spencer Phillip Pajk ,  Brett Joseph Prigaro ,  Li Ren ,  Eugene Tarlton

IPC分类号： C07D403/12 ,  C07D239/90 ,  C07D239/91 ,  A61K31/4184 ,  A61K45/06

摘要： Provided herein are compounds of the Formula I: and pharmaceutically acceptable salts, solvates and polymorphs thereof, wherein L, X1, R1, R2, R3, R4, R5 and R6 are as defined herein, for the treatment of BRAF-associated diseases and disorders, including BRAF-associated tumors, including malignant and benign BRAF-associated tumors of the CNS and malignant extracranial BRAF-associated tumors.

公开(公告)号：US20210380570A1

公开(公告)日：2021-12-09

申请号：US17053273

申请日：2019-05-06

申请人： Mirati Therapeutics, Inc. ,  Array BioPharma, Inc.

发明人： Matthew Arnold Marx ,  Matthew Randolph Lee ,  James F. Blake ,  Mark Joseph Chicarelli ,  Jay Bradford Fell ,  John P. Fischer ,  Erik James Hicken ,  Pavel Savechenkov ,  Tony Tang ,  Guy P.A. Vigers ,  Henry J. Zecca

IPC分类号： C07D413/14 ,  C07D413/06 ,  A61P35/00

摘要： The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.

公开(公告)号：US20180086758A1

公开(公告)日：2018-03-29

申请号：US15717700

申请日：2017-09-27

申请人： ARRAY BIOPHARMA INC.

发明人： Mark Laurence Boys ,  Robert Kirk DeLisle ,  Erik James Hicken ,  April L. Kennedy ,  David A. Mareska ,  Fredrik P. Marmsäter ,  Mark C. Munson ,  Brad Newhouse ,  Bryson Rast ,  James P. Rizzi ,  Martha E. Rodriguez ,  George T. Topalov ,  Qian Zhao

IPC分类号： C07D471/04 ,  A61K31/496 ,  A61K45/06

摘要： Compounds of Formula I: and pharmaceutically acceptable salts thereof in which R1, R2, R3, R4, R5 and R6 have the meanings given in the specification, are inhibitors of cFMS and are useful in the treatment of fibrosis, bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases, pain and burns in a mammal.

公开(公告)号：US20180072723A1

公开(公告)日：2018-03-15

申请号：US15814279

申请日：2017-11-15

申请人： Mirati Therapeutics, Inc. ,  Array BioPharma Inc.

发明人： James F. Blake ,  Laurence E. Burgess ,  Mark Joseph Chicarelli ,  James Gail Christensen ,  Jay Bradford Fell ,  John P. Fischer ,  John J. Gaudino ,  Erik James Hicken ,  Ronald Jay Hinklin ,  Matthew Randolf Lee ,  Matthew Arnold Marx ,  Macedonio J. Mejia ,  Martha E. Rodriguez ,  Pavel Savechenkov ,  Tony P. Tang ,  Guy P.A. Vigers ,  Henry J. Zecca

IPC分类号： C07D471/04

CPC分类号： C07D471/04 ,  C07D519/00

摘要： The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.

公开(公告)号：US08987251B2

公开(公告)日：2015-03-24

申请号：US14057882

申请日：2013-10-18

申请人： Array BioPharma Inc.

发明人： Shelley Allen ,  Laura L. Celeste ,  T. Gregg Davis ,  Robert Kirk DeLisle ,  Julie Marie Hicks ,  Stefan D. Gross ,  Erik James Hicken ,  Leila J. Jackson ,  Nicholas C. Kallan ,  Joseph P. Lyssikatos ,  Fredrik P. Marmsater ,  Mark C. Munson ,  Jed Pheneger ,  Bryson Rast ,  John E. Robinson ,  Stephen T. Schlachter ,  George T. Topalov ,  A. Dale Wright ,  Qian Zhao

IPC分类号： A61K31/437 ,  C07D471/04 ,  C07D451/06 ,  C07D519/00

CPC分类号： C07D471/04 ,  A61K31/437 ,  C07D451/06 ,  C07D519/00

摘要： Provided herein is a method of treating a PIM-1 and/or PIM-2 and/or PIM-3 kinase-mediated condition in a mammal, which comprises administering to said mammal a therapeutically effective amount of a compound of Formula I: in which A, B, R1, R1a, R2, R3, R4, R5, R6, and R7 have the meanings given in the specification.

摘要翻译： 本文提供了一种在哺乳动物中治疗PIM-1和/或PIM-3和/或PIM-3激酶介导的病症的方法，其包括向所述哺乳动物施用治疗有效量的式I化合物：其中 A，B，R1，R1a，R2，R3，R4，R5，R6和R7具有说明书中给出的含义。

公开(公告)号：US20140045835A1

公开(公告)日：2014-02-13

申请号：US14054459

申请日：2013-10-15

申请人： Array BioPharma Inc.

发明人： Shelley Allen ,  Robert Kirk DeLisle ,  Julie Marie Hicks ,  Erik James Hicken ,  Joseph P. Lyssikatos ,  Fredrik P. Marmsater ,  Mark C. Munson ,  John E. Robinson ,  Qian Zhao

IPC分类号： C07D471/04

CPC分类号： C07D471/04

摘要： Provided herein are methods of treating diseases mediated by PIM-1 and/or PIM-2 and/or PIM-3 kinases by administering to a mammal in need thereof a therapeutically effective amount of a compound of Formula I: in which B, R1, R1a, R2, R3, R4, R5, R6, R7, R10 and R11 have the meanings given in the specification.

摘要翻译： 本文提供了通过向有需要的哺乳动物施用治疗有效量的式I化合物来治疗由PIM-1和/或PIM-2和/或PIM-3激酶介导的疾病的方法：其中B，R1， R1a，R2，R3，R4，R5，R6，R7，R10和R11具有说明书中给出的含义。